A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
Recruiting · NCT06823752 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia. | Dyssomnias, Frontotemporal Lobar Degeneration, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Pick disease, Plaque, Amyloid, Sleep Disorders, Intrinsic, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, insomnia, nervous system disorder, psychiatric disorder, sleep-wake disorder | Recruiting | Phase 2 | 2026-09-18 | NCT06823752 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Woolcock Institute of Medical Research | 11 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Woolcock Institute of Medical Research | Macquarie Park | Australia | 10 |